Cufence is a medicine used to treat patients aged 5 years and older with Wilson's disease, a genetic condition in which copper absorbed from food builds up in the body, particularly in the liver and the brain, causing damage. Cufence is used in patients who cannot take D-penicillamine, another medicine for this condition. Cufence contains the active substance trientine dihydrochloride.
Therapeutic Indication
### Therapeutic indication Cufence is indicated for the treatment of Wilson’s disease in patients intolerant to D-Penicillamine therapy, in adults and children aged 5 years or older.
Therapeutic Area (MeSH)
ATC Code
A16A
ATC Item
其它消化道和代谢药物
Pharmacotherapeutic Group
Other alimentary tract and metabolism products
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| trientine dihydrochloride | N/A | 曲恩汀 |
EMA Name
Cufence
Medicine Name
Cufence
Aliases
N/ANo risk management plan link.
